SELLAS Life Sciences (SLS) Long-Term Debt Repayments (2014 - 2018)
SELLAS Life Sciences (SLS) posted quarterly Long-Term Debt Repayments of $76000.0 for Q4 2018, down 36.67% year-over-year from $120000.0 in Q4 2017, and down 98.9% quarter-over-quarter from $6.9 million in Q3 2018.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Long-Term Debt Repayments (2014 - 2018) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Long-Term Debt Repayments for 5 consecutive years, with $76000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Long-Term Debt Repayments fell 36.67% year-over-year to $76000.0; the TTM figure through Sep 2019 stood at $76000.0 (down 99.01% YoY), while the FY2018 annual figure was $7.6 million, up 1506.98% from the prior year.
- Long-Term Debt Repayments declined to $76000.0 in Q4 2018 per SLS's latest filing, from $6.9 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $6.9 million in Q3 2018 and bottomed at $1000.0 in Q3 2017.
- Historically, Long-Term Debt Repayments has averaged $1.1 million across 5 years, with a median of $858000.0 in 2014.
- Annual changes were most pronounced in 2017 — Long-Term Debt Repayments tumbled 90.61% — and 2018, when it soared 693500.0%.
- SELLAS Life Sciences' Long-Term Debt Repayments stood at $858000.0 in 2014, then increased by 17.6% to $1.0 million in 2015, then declined by 20.71% to $800000.0 in 2016, then plunged by 85.0% to $120000.0 in 2017, then sank by 36.67% to $76000.0 in 2018.
- Business Quant data shows SLS's Long-Term Debt Repayments at $76000.0 in Q4 2018, $6.9 million in Q3 2018, and $589000.0 in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 76,000.00 |
| Sep 30, 2018 | 6.94 Mn |
| Mar 31, 2018 | 589,000.00 |
| Dec 31, 2017 | 120,000.00 |
| Sep 30, 2017 | 1,000.00 |
| Jun 30, 2017 | 352,000.00 |
| Dec 31, 2016 | 800,000.00 |
| Jun 30, 2016 | 3.75 Mn |
| Mar 31, 2016 | 1.03 Mn |
| Dec 31, 2015 | 1.01 Mn |
| Sep 30, 2015 | 988,000.00 |
| Jun 30, 2015 | 967,000.00 |
| Mar 31, 2015 | 947,000.00 |
| Dec 31, 2014 | 858,000.00 |
| Sep 30, 2014 | 901,000.00 |
| Jun 30, 2014 | 4,000.00 |
| Mar 31, 2014 | 3,000.00 |